MDx/CDx Focus: Crescendo’s Vectra DA Gets Medicare Coverage; Cobas HPV … – GenomeWeb

MDx/CDx Focus: Crescendo's Vectra DA Gets Medicare Coverage; Cobas HPV
GenomeWeb
The FDA approved the Cobas HPV Test in 2011 as a tool to assess whether patients have high-risk Human Papillomavirus genotypes. Currently, the test is indicated for those 21-years or older with an abnormal Pap test, or meant to be used alongside a Pap 

View full post on hpv – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *